Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapy

Haifa Kathrin Al-Ali • 19 Jun 2020
EHA 2020
Myelofibrosis Myeloproliferative Neoplasms Navtemadlin Ruxolitinib

Haifa Kathrin Al-Ali, MD, University Hospital of Halle, Halle, Germany, discusses KRT‑232, a murine double minute 2 inhibitor (MDM2I), for myelofibrosis relapsed or refractory (R/R) to Janus‑associated kinase (JAK) inhibitor treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Haifa Kathrin Al-Ali

Novel approaches to upfront management of myelofibrosis 14:17
Novel approaches to upfront management of myelofibrosis
Donal McLornan et al. • 27 Jun 2025
Unmet needs in polycythemia vera: improving symptoms & qualify of life 2:57
Unmet needs in polycythemia vera: improving symptoms & qualify of life
Haifa Kathrin Al-Ali • 11 Jun 2023
Pelabresib in myelofibrosis: the MANIFEST trials 1:34
Pelabresib in myelofibrosis: the MANIFEST trials
Haifa Kathrin Al-Ali • 11 Jun 2023
Phase I/II study of a novel BET inhibitor, BMS-986158, alone & with ruxolitinib or fedratinib in MF 2:04
Phase I/II study of a novel BET inhibitor, BMS-986158, alone & with ruxolitinib or fedratinib in MF
Haifa Kathrin Al-Ali • 11 Jun 2023

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals